Spots Global Cancer Trial Database for Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

Official Title: Phase II Study, Multicenter, Randomized, Stratified, Evaluating the Efficacity of Weekly Paclitaxel, With or Without Bevacizumab in the Treatment of Metastatic or Locally Advanced Angiosarcomas Not Accessible to Surgery Treatment.

Study ID: NCT01303497

Conditions

Angiosarcoma

Interventions

Paclitaxel

Bevacizumab

Study Description

Brief Summary: Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma

Detailed Description: Randomization is stratified : * angiosarcoma in irradiated region : yes / no * visceral angiosarcoma : yes / no All patient will received a maximum of 6 cycles of weekly Paclitaxel (Arm A and B) in association or not with Bevacizumab (ArmB). 1 cycle = 28 days Treatment by Bevacizumab is to continue beyond the 6th cycle, until disease progression or unacceptable toxicity Arm A and B: Day 1, D8 and D15 Paclitaxel : 90 mg/m², IV weekly with premedication Arm B : Day 1 and D15 Bevacizumab : 10 mg/kg and then, Bevacizumab : 15 mg/kg/3 weeks until disease progression or unacceptable toxicity